Although one gene therapy for RPE65-linked retinal dystrophies is available (Russell et al., 2017), clinical interventions to treat other widespread retinal dystrophies based on optogenetics (Simunovic et al., 2019) and stem cells (Maeda et al., 2019) are still in preclinical experimentation and/or in early phases of testing in humans. The gene discussed is RPE65; the disease is Retinal dystrophy.